Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging - Full Text View

Sponsors and Collaborators:	Institute of Skin and Product Evaluation, Italy Aromtech Ltd.
Information provided by:	Institute of Skin and Product Evaluation, Italy
ClinicalTrials.gov Identifier:	NCT00767156

Purpose

The effect of oral supplementation of SBA24 sea buckthorn oil capsule and topical application of Omega7 sea buckthorn cream on skin ageing is studied in a single blind, parallel study.

Condition	Intervention
Skin Aging	Other: Omega7 Sea Buckthorn Oil Cream Other: Base cream Dietary Supplement: SBA24 Sea Buckthorn Oil Capsule

MedlinePlus related topics: Dietary Supplements Skin Aging

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Supportive Care, Randomized, Single Blind (Subject), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Subjective and Instrumental Evaluation of the Effects of Treatments With Two Sea Buckthorn Oil Products on Cutaneous Aging

Further study details as provided by Institute of Skin and Product Evaluation, Italy:

Primary Outcome Measures:

Decrease of signs of skin aging [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Subjects self-assessment of the efficacy of the treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	60
Study Start Date:	October 2008
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	November 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
SBA24 capsule plus Omega7 cream: Active Comparator the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream	Dietary Supplement: SBA24 Sea Buckthorn Oil Capsule The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
SBA24 capsule plus base cream: Active Comparator the subjects took SBA24 sea buckthorn oil capsule and apply a base cream	Dietary Supplement: SBA24 Sea Buckthorn Oil Capsule Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
Omega7 Cream: Active Comparator The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day	Other: Omega7 Sea Buckthorn Oil Cream The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
Base cream: Placebo Comparator The subjects use base cream on the face, twice per day	Other: Base cream The subjects use the base cream on the face, twice per day

Detailed Description:

The study is carried out on two groups of female volunteers, 30 in each group, of age 30 to 60 years, in compliance with the principles established by the World Medical Association in the Declaration of Helsinki. In group I, the subjects took SBA24 sea buckthorn oil capsule (2 x 2 capsules per day) and apply two different creams on the face, one cream on each half of the face, twice per day. In group II, the subjects apply only the two creams, one cream on each half of the face, twice per day, for 8 weeks.

The assessment is performed on the skin surface of the periocular areas.

The efficacy of the active products is assessed on the skin face at the beginning, after 4 weeks and after 8 weeks of treatment using the following instrumental measurements:

cutaneous elasticity (CUTOMETER SEM 575 Courage & Khazaka);
cutaneous hydration level (CORNEOMETER CM 825 Combi 3 Courage & Khazaka);
cutaneous roughness by cutaneous replicas and image analysis (Quantilines, Monaderm); Determination of benefit is based on instrumental measurements and subject self-assessment questionnaires.

Eligibility

Ages Eligible for Study:	30 Years to 60 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Female subjects 30 - 60 years old with Fitzpatrick skin type I-IV & in good general health, with facial skin manifestation related to photoaging (wrinkles, dyschromias, tissue looseness etc.)
Subjects must have discontinued the use of topical retinoid products for 6 months prior to study entry and of systemic retinoids for 1 year prior to study entry.
Subjects must have discontinued the use of topical alpha-hydroxy, &/or beta-hydroxy products for 45 days prior to study entry & all other topical facial medication to the skin immediately prior to study entry.
Subjects must have discontinued the use of systemic antiaging or antioxidant products for at least 2 months prior to study entry.
Subjects must be willing & able to follow all study directions & to commit to all follow-up visits for the duration of the study.
Subjects must have completed the informed consent process.
Subjects must be willing to avoid direct daily sun exposure on the face or the use of tanning beds.

Exclusion Criteria:

Pregnant or nursing females.
Subjects with a history of unusual skin reactions to skin care toiletry products, cosmetics, or sensitivity to any of the test article components.
Previous facial treatments with any dermal fillers (i.e. collagen, hyaluronic acid etc)
Concurrent therapy, systemic diseases, or skin disorders (such as eczema, psoriasis, severe acne etc.) which may interfere with the evaluation of the test articles or increase risk to the subject.
Subjects currently involved in another clinical investigation or who have been involved within a period of 30 days prior to admission in this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00767156

Locations

Italy
ISPE Srl
Milan, Italy, 20125

Sponsors and Collaborators

Institute of Skin and Product Evaluation, Italy

Aromtech Ltd.

Investigators

Principal Investigator:

Adriana Bonfigli, PhD

Research Director

More Information

Responsible Party:	ISPE ( Adriana Bonfigli )
Study ID Numbers:	E11UE15UE25US14C
Study First Received:	October 3, 2008
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00767156
Health Authority:	Italy: Ethics Committee

Keywords provided by Institute of Skin and Product Evaluation, Italy:

Sea buckthorn oil, Oral and topical treatment, Skin aging

ClinicalTrials.gov processed this record on January 16, 2009